Company profile · Sponsor
Seqirus
Seqirus (Australia) Pty Ltd
- Pipeline
- 9
- Drugs
- 11
- Patents
- 0
Quick answer
Seqirus (E60418A) is a pharma company. headquartered in AU. listed on TGA. NovaPharmaNews links 9 pipeline programs, 11 drugs, and 0 patents to this profile..
Company facts
Pipeline (9)
Search pipeline →-
Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)
Seqirus
Influenza Virus
1 trial -
Influenza Virus Vaccine
Seqirus
Influenza
1 trial -
Investigational aQIVc
Seqirus
Influenza, Human
1 trial -
MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)
Seqirus
Influenza
1 trial -
QIVc
Seqirus
Influenza, Human
1 trial -
aQIV or aTIV
Seqirus
Influenza, Human
1 trial -
H5N1 antigen combined with MF59 adjuvant
Seqirus
Influenza, Human
1 trial -
Trivalent influenza vaccine (TIVc)
Seqirus
Influenza
1 trial -
CSL Limited Influenza Vaccine
Seqirus
Influenza
1 trial
Drugs (11)
Search drugs →-
avacopan
TAVNEOS
L04 -
difelikefalin
KORSUVA
V03AX -
diphtheria + tetanus vaccine
ADT BOOSTER
-
ferric carboxymaltose
FERINJECT
-
icosapent ethyl
VAZKEPA
C10AX -
iron sucrose
VENOFER
-
liquid paraffin + glycerol + tyloxapol + poloxamer-188 + trometamol hydrochloride + trometamol + cetalkonium chloride
CATIONORM
-
patiromer
VELTASSA
V03AE09 -
sucroferric oxyhydroxide
VELPHORO
V03AE05 -
tapentadol
PALEXIA SR
-
tramadol
TRAMAL
Frequently asked questions
What is Seqirus?
Seqirus (E60418A) is a pharma company. headquartered in AU. listed on TGA. NovaPharmaNews links 9 pipeline programs, 11 drugs, and 0 patents to this profile..
What pipeline programs does Seqirus sponsor?
We track 9 ClinicalTrials.gov-linked programs for Seqirus, including Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV) and 8 more. Open each program for phase, modality, NCT IDs, and indication details.
Where does Seqirus company data come from?
Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.